C&R Research and LegoChem Biosciences Sign Joint R&D of Next Generation Antibiotics
C&R Research and LegoChem Biosciences Sign Joint R&D of Next Generation Antibiotics
MOU Signed for Joint R&D and Investment of LegoChem ‘Delpazolid’..Global Phase 2b Cooperation
Seoul, Korea, April 2, 2019 — C&R Research announced the signing of a memorandum of understanding (MOU) with LegoChem. The goal of the agreement is to develop the next generation gram-positive bacterial antibiotic Delpazolid and to establish a strategic partnership to advance to domestic and global markets.
Through the agreement, both parties will collaborate in various areas to develop Delpazolid (LCB01), which is currently undergoing phase 2a in Korea; they will collaborate in joint R&D and investment, clinical development and licensing, infrastructure sharing for new business discovery, global advancement, and strategy development for global expansion.
C&R Research will be participating in the global phase 2b clinical trial, which will be held in the U.S., following the analysis of Delpazolid’s phase 2a results.
Delpazolid, a new antibiotic of LegoChem Bio, is an oxazolidine-affiliated drug that hinders the biosynthesis of bacterial proteins by combining with the V domain of the 23S rRNA molecule. It has been designated as an orphan drug, certified as Qualified Infectious Disease Product (QIDP), and received Fast Track designation by the U.S. Food and Drug Administration (FDA). Delpazolid was also noted for its greater efficacy in Multidrug-resistant Tuberculosis than Pfizer’s Zyvox, according to a study result by a Chinese tuberculosis institute.
C&R Research is one of the leading CROs in South Korea that was established in 1997, and it has conducted more than 1,200 global clinical trials. The company entered the global markets of Singapore, Malaysia, Australia, etc., beginning with the establishment of a corporation in Beijing, China in 2010. A C&R Research official stated, “Based on our clinical trial infrastructure and expertise, the two companies will endeavor to create successful cases in the next generation antibiotic market to enhance patients’ access to innovative treatment.”
